A Holy Grail in the quest to end cancer Targeted therapies and chemotherapeutics have helped cut cancer deaths dramatically in the last few decades. In the US, the overall mortality rate of 251/100,000 patients in 1991 had fallen by 2016 … more ➔
Blood routine testing in sepsis and AHF ah... Pilot routine tests with the vasoactive biomarker bio-ADM confirm clinical test results. Medical leaders back actionable utility of the marker in medical decision-making in septic shock and congestive … more ➔
Bioengineers to standardise biomanufacturi... Biomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. … more ➔
No Games. Just Deals!As resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? … more ➔
SPC manufacturing waivers: A blow to innov... The EUs Big Pharma companies have sharply criticised the European Parliaments Legal Committee JURI backing of an amended proposal of the European Commission (EC) to introduce a supplementary protection … more ➔
Financing AMR innovation discussed globall... Financing of AMR innovation is shifting gears in early 2019. US AMR accelerator CARB-X has expanded its global reach, the Novo REPAIR impact fund reflects on their first and upcoming investments, and … more ➔
“We need to grow” Why the US AMR accelerator aims to expand its reach in Europe to support antibacterial R&D, and why it is important to bundle global resources, explains Kevin Outterson, Executive Director of CARB-X. more ➔
Digital solutions to serialisation Its only been nine years since the first blockchain technology applications in finance were introduced. Big players are now working to use distributed computing to protect pharma logistics from counterfeit … more ➔
Race against time After a quick start out the gates in 2012, the European Commission proceeded to carry out a lengthy review of its bioeconomy strategy – slamming the brakes on investor interest in EU biotechs developing … more ➔
Can machines learn to discover drugs? Take the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is … more ➔
